CN103168100B - 用于制备流感病毒的永久人细胞系 - Google Patents

用于制备流感病毒的永久人细胞系 Download PDF

Info

Publication number
CN103168100B
CN103168100B CN201180050018.7A CN201180050018A CN103168100B CN 103168100 B CN103168100 B CN 103168100B CN 201180050018 A CN201180050018 A CN 201180050018A CN 103168100 B CN103168100 B CN 103168100B
Authority
CN
China
Prior art keywords
cells
influenza virus
medium
cell
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180050018.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103168100A (zh
Inventor
G.希德纳
U·赖克勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cevec Pharmaceuticals GmbH
Original Assignee
Cevec Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cevec Pharmaceuticals GmbH filed Critical Cevec Pharmaceuticals GmbH
Publication of CN103168100A publication Critical patent/CN103168100A/zh
Application granted granted Critical
Publication of CN103168100B publication Critical patent/CN103168100B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201180050018.7A 2010-08-16 2011-08-16 用于制备流感病毒的永久人细胞系 Active CN103168100B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102010037008.8 2010-08-16
DE102010037008 2010-08-16
DE102011050353 2011-05-13
DE102011050353.6 2011-05-13
PCT/DE2011/075194 WO2012041311A1 (de) 2010-08-16 2011-08-16 Permanente humane amniozyten zelllinie zur herstellung von influenzaviren

Publications (2)

Publication Number Publication Date
CN103168100A CN103168100A (zh) 2013-06-19
CN103168100B true CN103168100B (zh) 2016-04-13

Family

ID=44936126

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180050018.7A Active CN103168100B (zh) 2010-08-16 2011-08-16 用于制备流感病毒的永久人细胞系

Country Status (19)

Country Link
US (1) US20130344569A1 (enExample)
EP (1) EP2606128B1 (enExample)
JP (1) JP5928843B2 (enExample)
KR (1) KR101780257B1 (enExample)
CN (1) CN103168100B (enExample)
AU (1) AU2011307655B2 (enExample)
BR (1) BR112013003766B1 (enExample)
CA (1) CA2808453C (enExample)
DE (1) DE112011102737A5 (enExample)
DK (1) DK2606128T3 (enExample)
ES (1) ES2524894T3 (enExample)
IL (1) IL224728A (enExample)
MX (1) MX337687B (enExample)
PL (1) PL2606128T3 (enExample)
PT (1) PT2606128E (enExample)
RU (1) RU2565546C2 (enExample)
SG (1) SG187863A1 (enExample)
TW (1) TW201211257A (enExample)
WO (1) WO2012041311A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024537896A (ja) 2021-10-18 2024-10-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞
AR127674A1 (es) 2021-10-18 2024-02-21 Regeneron Pharma Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios
CN121343924A (zh) * 2024-07-15 2026-01-16 干细胞转化研究中心有限公司 极早期干细胞在流感病毒制备、检测和药物筛选中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101310014B (zh) * 2005-11-16 2012-05-30 塞维克制药有限责任公司 制备永久人细胞系的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
US7410798B2 (en) * 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US20050170463A1 (en) 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) * 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
ES2526170T3 (es) * 2004-12-23 2015-01-07 Medimmune, Llc Línea celular MDCK no tumorigénica para propagar virus
ES2402061T3 (es) * 2005-10-17 2013-04-26 Medimmune, Llc Método de aumento de la replicación del virus influenza
AU2007347716B2 (en) * 2006-09-15 2013-06-20 Medimmune, Llc MDCK cell lines supporting viral growth to high titers and bioreactor process using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101310014B (zh) * 2005-11-16 2012-05-30 塞维克制药有限责任公司 制备永久人细胞系的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EB病毒转化外周血淋巴细胞建立永生细胞系方法的研究;魏军等;《中华检验医学杂志》;20071231;第30卷;1176-1179 *
利用基因敲入技术在肝癌细胞系中稳定表达HBV的X抗原;黄婷婷等;《医学分子生物学杂志》;20081231;第5卷;299-302 *

Also Published As

Publication number Publication date
WO2012041311A1 (de) 2012-04-05
AU2011307655B2 (en) 2015-12-17
MX2013001772A (es) 2013-06-03
EP2606128B1 (de) 2014-09-10
ES2524894T3 (es) 2014-12-15
CA2808453C (en) 2020-05-05
IL224728A (en) 2016-05-31
CA2808453A1 (en) 2012-04-05
KR101780257B1 (ko) 2017-09-21
TW201211257A (en) 2012-03-16
PL2606128T3 (pl) 2015-02-27
SG187863A1 (en) 2013-03-28
EP2606128A1 (de) 2013-06-26
RU2565546C2 (ru) 2015-10-20
RU2013110786A (ru) 2014-09-27
KR20130097191A (ko) 2013-09-02
BR112013003766B1 (pt) 2021-08-24
JP5928843B2 (ja) 2016-06-01
JP2013537543A (ja) 2013-10-03
BR112013003766A2 (pt) 2016-05-31
CN103168100A (zh) 2013-06-19
AU2011307655A1 (en) 2013-03-21
US20130344569A1 (en) 2013-12-26
DE112011102737A5 (de) 2013-06-06
DK2606128T3 (en) 2014-12-01
MX337687B (es) 2016-03-15
PT2606128E (pt) 2014-12-09

Similar Documents

Publication Publication Date Title
AU2006236910B2 (en) Vaccine against pandemic strains of influenza viruses
US20100196419A1 (en) Enhancement of glycoprotein incorporation into virus-like particles
CN104812894B (zh) 新型mva病毒及其用途
US20100099745A1 (en) Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors
US20260041761A1 (en) Pharmaceutical composition for resisting infection with sars-cov-2 or mutant thereof, and combined drug thereof
WO1996000583A1 (en) Polynucleotide vaccine for papillomavirus
TW202206598A (zh) 對抗ＳＡＲＳ－ＣｏＶ－２之疫苗及其製品
WO2023023940A1 (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
WO2012058493A2 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
CN103168100A (zh) 用于制备流感病毒的永久人细胞系
CN113388588B (zh) 表达牛疱疹病毒Ⅰ型gB基因的重组牛结节疹病毒及其应用
Li et al. Development and characterization of Rift Valley fever virus-like particles
AU2012216357B2 (en) Vaccine against pandemic strains of influenza viruses
US20230310574A1 (en) Multivalent vaccines against turkey arthritis reovirus
Mazurkova et al. Comparative analysis of reproduction of influenza virus strains in cell lines perspective for the creation of cultural vaccines grown on nutrient medium on the basis of rise flour protein hydrolysate
Hussein et al. Protective efficacy of a prime-boost protocol using H5-DNA plasmid as prime and inactivated H5N2 vaccine as the booster against the Egyptian avian influenza challenge virus
HK1117743A (en) Vaccine against pandemic strains of influenza viruses
Parker Comparison of Codon Optimized and Non-Optimized Influenza HA DNA Vaccines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: G Xidena

Inventor after: U Reich

Inventor before: G Xidena

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: SCHIEDNER GUDRUN TO: SCHIEDNER GUDRUN REICHL UDO

C14 Grant of patent or utility model
GR01 Patent grant